Clinical Trial Update: Cabozantinib Dose Skipping as an Alternative to Dose Reductions [Phase 2]

View source ↗

Summary

A Phase 2 study update examining cabozantinib dose skipping as an alternative to dose reductions in renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)

Snippet

Sponsor: dr. Tom van der Hulle | Conditions: Renal Cell Carcinoma (RCC) | Phase 2 | Status: RECRUITING